ACAD vs ACN · P/E 15, rev $576.0M vs P/E 24, rev $17.60B
ACADIA Pharmaceuticals Inc (ACAD) versus Accenture plc (ACN) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Accenture plc (ACN) is a information technology services company listed on US.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported ACN revenue for 2025-08-31 was $17.60B. Net income was $1.41B. Revenue was down 0.7% from 2025-05-31 to 2025-08-31. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
Not investment advice. Open the ACAD and ACN stock pages for the full models.
Not investment advice.